Thu, Jul 31, 2014, 4:12 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Prana Biotechnology Limited Message Board

SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Dr. Peter Smith.

    by inversor86 14 hours ago

    Ira is a skilled scientist but I've seen him on video, you don't want him handling Business Development.

  • Reply to

    Last Friday.

    by toxxxicsludge Jul 29, 2014 8:14 AM

    July 15th, 2014:
    Yellen's comments on the biotech's ..."valuation metrics in some sectors do appear substantially stretched—particularly those for smaller firms in the social media and biotechnology industries"...
    Sorry. I thought most involved in the stock market knew that. Her comments took place at the exact time frame that Prana was threatening a technical breakout. A rebound from from a throwback to the breakout line to be exact. Regardless, that's done. Thousands of other stocks out there to choose from. Either a breakout takes place, or it doesn't. Nothing to sweat over. I still own a little PRAN.

  • 1.Are there any other companies that are developing drugs for AD? 2:Did not SYN dabble in this for awhile? 3: Anybody no why JAZZ soared like it did? I think prevention of a debilitating disease such as AD, which can begin much earlier than one would think, should be prioritized over fibro. Granted PRAN hasn't the drug to mkt yet, but still

    Sentiment: Hold

  • HDBuzz ‏@HDBuzzFeed

    Brain cells called astrocytes might play a bigger role than previously thought in Huntington's disease enDOThdbuzzDOTnet/170

    Sentiment: Strong Buy

  • So far I have not been able to get this whole paper but here's the abstract. Astrocytes were becoming important topic at the AAIC and appears to be of growing importance with HD.

    DOI: 10.1016/j.neuint.2012.08.017
    Ivo F. Scheiber,
    Ralf Dringen
    Abstract

    Copper is an essential element that is required for a variety of important cellular functions. Since not only copper deficiency but also excess of copper can seriously affect cellular functions, the cellular copper metabolism is tightly regulated. In brain, astrocytes appear to play a pivotal role in the copper metabolism. With their strategically important localization between capillary endothelial cells and neuronal structures they are ideally positioned to transport copper from the blood–brain barrier to parenchymal brain cells. Accordingly, astrocytes have the capacity to efficiently take up, store and to export copper. Cultured astrocytes appear to be remarkably resistant against copper-induced toxicity. However, copper exposure can lead to profound alterations in the metabolism of these cells. This article will summarize the current knowledge on the copper metabolism of astrocytes, will describe copper-induced alterations in the glucose and glutathione metabolism of astrocytes and will address the potential role of astrocytes in the copper metabolism of the brain in diseases that have been connected with disturbances in brain copper homeostasis.

    Sentiment: Strong Buy

  • Reply to

    34M cash

    by brewman228 14 hours ago

    They already have sizeable grants from the UK and from MJF foundations for PD. With all the safety data that we have, two trials that say PBT2 reduces hippocampal atrophy on both the REACH2HD and IMAGINE trials, EF results from REACH2HD and results from Phase 2a trial for AD, there is enough evidence right now for PBT2 to obtain fast track designation in US. This would speed PBT2 to market for HD sufferers and doctors could prescribe off-label for AD. FDA would then work with pran to answer remaining questions and limit cost associated with Phase 3 for HD. My feeling is that this is what Shoulson was tasked to do and is what Kempler referred to as the package in the interview with Tiki.

    Sentiment: Strong Buy

  • Reply to

    Dr. Peter Smith.

    by inversor86 14 hours ago

    Getting anything out of IR is very difficult. Good that you got by them Inversor. I think Peter Smith was not the right person to do what we need right now and Shoulson is much better suited to get HD through FDA. The fast track application process is confidential so they may have already submitted something and we wouldn't necessarily know about it until its approved and Prana tells us. FDA won't.

    I've maintained that with all the safety data that we have, two trials that say PBT2 reduces hippocampal atrophy on both the REACH2HD and IMAGINE trials, EF results from REACH2HD and results from Phase 2a trial for AD, there is enough evidence right now for PBT2 to obtain fast track designation in US. This would speed PBT2 to market for HD sufferers and doctors could prescribe off-label for AD. My feeling is that this is what Shoulson was tasked to do and is what Kempler referred to as the package in the interview with Tiki.

    Sentiment: Strong Buy

  • Reply to

    34M cash

    by brewman228 14 hours ago

    Enough for a phase 3 trial for HD with 500 participants. Plus, they will receive additional funding from the AD organizations as well.

    Looks good for getting Phase III done and doing a PHase I for PBT434 if they want.

    Sentiment: Buy

  • Reply to

    New paper by Bush about copper

    by pivalde 12 hours ago

    Conclusion
    Inherited disorders of Cu metabolism, such as Menkes and Wilson’s disease display complex
    neurodegenerative features, which highlight the importance of copper homeostasis (Tümer and
    Møller, 2010). Moreover, micromolar concentrations of copper (up to 400 μM) are present in senile
    plaques in AD brains (Lovell et al., 1998), which could be a source of copper for the neurons
    surrounding these pathological structures. Brain copper deficiency is a characteristic feature of
    Menkes disease, which affects brain physiology, since patients display gray matter degeneration,
    hippocampal neuronal loss and Purkinje cell abnormalities (Okeda et al., 1991). AD is another brain
    pathology characterized by neurodegeneration that produces a broad spectrum of symptoms that
    have been linked to copper brain depletion since cupro-proproteins such as ceruloplasmin are
    decreased (Connor et al., 1993; Bush, 2003) or less active as observed for superoxide dismutase 1
    (Omar et al., 1999; Maynard et al., 2005). Currently, the relationship between copper and
    neuroproteostasis within the CNS in health and pathological conditions is poorly understood. Hence,
    further studies are required to determine how neuronal excitability is linked to changes in synaptic
    proteins promoted by copper (Gaier et al., 2013). The studies described here provide a new
    perspective on how copper can regulate the communication between neurons by modifying the
    protein configuration and strength of neurotransmission within the CNS.

  • Reply to

    34M cash

    by brewman228 14 hours ago

    4.2M in research and development was spent. This was likely final payment to Austin Health other trial related payments and possibly the statistical group and data evaluation group.

    The 16M income we saw come in is stated here as "proceeds from issue of shares, options, etc"

    Sentiment: Strong Buy

  • Reply to

    34M cash

    by brewman228 14 hours ago

    The market capital was yesterday US$ 94M. So the value of the company without the cash is now a bit above US$ 60M. To me it is very low if you think that the drug it has can slow down the atrophy rate of brain as I do think ( a trend in statistical analysis in a very small population). I even think that it is a good possibility that PBT2 can totally stop the progression of the atrophy if the dosage of PBT2 is increased and/or the treatment is given longer time than 1y ( as it is in the extension study). IMO there is no reason why PBT2 would not work in humans as it did in the animal experiments after PBT2 demonstrated this slowing of atrophy rate in the Imagine study. There is now proof that most likely PBT2 works in the same way both in the mouse models and in humans.
    The dosage in Ihe imagine study was almost only 10% what was used in the animal studies. It is difficult to compare treatment time between the mouse studies and the Imagine study but with a low dosage you perhaps need to wait the results longer. Humans live some 40 times longer than mice and so the treatment time of mice for 12 days could somehow correspond 480 days of human life (?????,). Usually it takes a minimum of 1y to recover from brain injury or stroke and improvement happens usually up to 3 years. So I do expect that the positive trend seen after the 1st year will get stronger.
    So with some UD$ 30M cash the value of the company on the Wall Street is very small. I do not think that Wall Street will change it's valuation much before any further evidence, but I am sure Big Pharma scientist understand the value of PBT2, it is much more than they have spent on their AD drugs.

  • It is in Front Aging Neurosci, it is free on the net.

    Copper: from neurotransmission to neuroproteostasis.

    Opazo CM, Greenough MA, Bush AI.

  • Reply to

    Dr. Peter Smith.

    by inversor86 14 hours ago

    Could be that Ira Shoulson started to work at least on some of those tasks Smith had. I mean to get PBT2 accepted in HD. Smith had some experience in that field but Ira Shoulson has much more.

  • Reply to

    34M cash

    by brewman228 14 hours ago

    That's a substantial amount of cash to burn though, I need to look into that.

  • Some here, myself included, had no luck getting a response about what was going on with our VP of Business Development. I managed to get on the phone with someone important at Prana. Though it was not the focus of our conversation I did ask about Smith. I was told his contract ran its course but Smith is still interested in working with Prana and is on call when they need him.

  • just posted lastest quarter results

  • My bull - stuff - o - meter just went off scale.

    Sentiment: Strong Buy

  • Your post would have been more creative and believable if you'd said Prana was a scam by 2 Eskimos operating from an igloo which was melting due to global warming.

    Sentiment: Strong Buy

  • ah goldie and gyoung the perfect couple. By the way gyoung you have almost had a decent call for two days now.

  • lol...trying to be nice nice...

    Sentiment: Hold

PRAN
2.19-0.07(-3.10%)4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.